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Protein kinase C (PKC) has a critical role in several signal transduction pathways, and is involved in renal cancer pathogenesis.
Bryostatin-1 modulates PKC activity and has antitumour effects in preclinical studies. We conducted a multicentre phase II clinical trial
in patients with advanced renal cancer to determine the response rate, immunomodulatory activity and toxicity of bryostatin-1 given
as a continuous 24h infusion weekly for 3 out of 4 weeks at a dose of 25mgm
 2. In all, 16 patients were recruited (11 males and five
females). The median age was 59 years (range 44–68). Patients had been treated previously with nephrectomy (8) and/or interferon
therapy (9) and/or hormone therapy (4) and/or radiotherapy (6). Eight, five and three patients had performance statuses of 0, 1 and
2, respectively. A total of 181 infusions were administered with a median of 12 infusions per patient (range 1–29). Disease response
was evaluable in 13 patients. Three patients achieved stable disease lasting for 10.5, 8 and 5.5 months, respectively. No complete
responses or partial responses were seen. Myalgia, fatigue, nausea, headache, vomiting, anorexia, anaemia and lymphopenia were the
commonly reported side effects. Assessment of biological activity of bryostatin-1 was carried out using the whole–blood cytokine
release assay in six patients, two of whom had a rise in IL-6 levels 24h after initiating bryostatin-1 therapy compared to pretreatment
values. However, the IL-6 level was found to be significantly lower at day 28 compared to the pretreatment level in all six patients
analysed.
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Renal cancer accounts for 2% of all cancers and the global
incidence is increasing (Parkin et al, 1999; Mathew et al, 2002).
Current modalities of therapy (including nephrectomy and/or
immunotherapy) have only modestly improved the survival rates
(Glaspy, 2002). Hence, there is a need to identify novel molecular
targets and cancer therapies to improve patient outcomes.
Protein kinase C (PKC) is a calcium and lipid- activated serine-
threonine protein kinase that has a central role in several signal
transduction pathways and is involved in the pathogenesis of renal
cancer (Pal et al, 1997; Fowler et al, 1998).
Bryostatin-1 is a highly oxygenated macrolide with a unique
polyacetate backbone isolated from the marine bryozoan ‘Bigula
neritina’. Bryostatin-1 causes isotype-specific PKC modulation and
preclinical studies confirm its anticancer activity (Dale and
Gescher, 1989; Kraft et al, 1989; Lilly et al, 1990; Schuchter et al,
1991; Stanwell et al, 1994). Bryostatin-1 also has significant
immunomodulatory activity (Mohr et al, 1987; Tuttle et al, 1992;
Philip et al, 1993).
Myalgia was the dose-limiting toxicity in several phase I human
trials. The other commonly reported side effects were fever, flu-like
symptoms, fatigue, anaemia, transient thrombocytopenia, phlebi-
tis, headache, hypotension, bradycardia, flushing, dyspnoea,
photophobia and eye pain (Prendiville et al, 1993; Grant et al,
1998; Weitman et al, 1999). Protein kinase C activity was
significantly modulated during bryostatin-1 infusion in peripheral
blood mononuclear cells (Varterasian et al, 1998). Previously, we
reported a phase I trial of bryostatin-1, where increases in plasma
IL-6 and TNF-a were seen within 24h of therapy and partial
responses were seen in two patients with melanoma (Philip et al,
1993). In another phase I trial of bryostatin-1 given as a 24h
intravenous infusion, weekly for 8 weeks, dose-limiting myalgia
occurred at a dose of 25mgm
 2. Four patients achieved favourable
disease responses (two patients had partial responses and two had
minor responses) (Jayson et al, 1995).
Based on the above biochemical, preclinical and clinical data, we
initiated a multicentre phase II study to determine the response
rate, immunomodulatory activity and toxicity of bryostatin-1
given as continuous 24h intravenous infusion weekly for 3 out of 4
weeks at a dose of 25mgm
 2 in renal cancer.
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lMATERIALS AND METHODS
Patient selection:
This multicentre phase II trial was conducted in compliance with
the requirements of the declaration adopted by the world
assemblies held at Helsinki, Tokyo, Venice and Hong Kong
(1989). Each participating centre was required to obtain local
research ethic committee approval prior to initiating the trial. All
patients provided written informed consent. Patients were eligible
to participate in the study if they had advanced, histologically
confirmed renal cell carcinoma with bidimensionally measurable
lesions and documented disease progression within 2 months prior
to entry. A performance status of 0,1 or 2 and an expected life
expectancy of greater than 3 months was necessary. Patients had to
have normal full blood counts (granulocyte count41.5 10
9l
 1,
total platelet count4100 10
9l
 1), normal renal function (serum
creatinine o150mM) and acceptable liver function tests (serum
bilirubin o20mM, transaminases o 2.5  normal). All patients
were required to have a central venous catheter inserted before
initiating therapy.
Treatment plan
Bryostatin-1 was supplied by the (National Cancer Institute, NCI
USA) as a two-part formulation. A 6ml vial containing 0.1mg
bryostatin-1 and 5mg povidone USP (as a bulking agent)
lyophilised from 40% t-butanol and a second vial of sterile PET
diluent (60% polyethylene glycol 400, 30% ethanol and 10% Tween
80). The lyophilised powder was reconstituted in 1ml of the PET
diluent and further diluted in 50ml of 0.9% sodium chloride, USP.
The resulting solution containing 2mgml
 1 of bryostatin-1 was
transferred to a 50ml non-PVC syringe. Brystatin-1 was adminis-
tered at a dose of 25mgm
 2 (concentration of 2mgml
 1) as a 24h
infusion (ambulatory pump) via central line weekly for 3 out of 4
weeks. As bryostatin-1 is adsorbed onto plastic surfaces, a ‘non-
poly vinyl chloride (PVC) Gish skin tunnelled central venous
catheter’ was inserted in all patients. Each 4-week block comprised
one cycle of treatment.
Evaluation protocol at baseline and during therapy
All participating patients were carefully monitored during therapy.
History, physical examination and performance status assessments
were performed at baseline, prior to each cycle of therapy and at
the end of treatment. Biochemical evaluation (serum Na, K,
glucose, urea, creatinine, alkaline phosphatase, total bilirubin, AST
and GGT) and haematological evaluation (Hb, white cell count and
platelet count) were performed at baseline, prior to each infusion
of therapy and at the end of treatment. Radiological evaluation (CT
scan, X-ray) was performed at baseline, after two cycles of
treatment and 8 weekly thereafter until disease progression. For
the assessment of biological responses, blood samples were
collected during the first month of therapy at set time points
(pretreatment, 24h, days 15 and 28).
Patients were evaluated for radiological disease response after
two cycles of therapy. Complete response (CR) was defined as
disappearance of all clinical evidence of active tumour for a
minimum of 4 weeks and normalisation of tumour markers and
tumour-related biochemical abnormalities. Partial response (PR)
was defined as 50% or greater decrease in the sum of the diameters
of measured lesions. Stable disease (SD) was defined as o50%
decrease or o25% increase in the sum of the longest perpendi-
cular lesion diameter. An increase of 425% in the size of any
measured lesion or appearance of new lesions was defined as
progressive disease (PD). Patients who achieved SD or showed
regressions after 2 months of therapy were planned to receive
further courses of bryostatin-1 with disease response assessments
done at 8-weekly intervals. Therapy was terminated at disease
progression, with the occurrence of a serious adverse event or at
patient’s request.
Toxicity evaluation was performed using National Cancer
Institute’s common toxicity criteria (NCI-CTC Version 2.0).
Toxicity was categorised as unlikely, possibly, probably or almost
certainly related to bryostatin-1. For patients who experienced 4
grade 2 myalgia and/ or headache (lasting for more than 7 days)
due to bryostatin-1, treatment delays for up to 1 week was allowed
and therapy restarted if the above symptoms settled. However, for
other grade 3–4 toxicity possibly, probably or definitely related to
bryostatin-1, treatment was terminated. No dose modification was
allowed in this study.
Laboratory procedures
TNF-a mediates the production of IL-6 in the whole blood when
stimulated by phytohaemagglutinin (PHA) in vitro. Therefore,
whole-blood samples were collected from six patients at four
different time points during a 28-day treatment cycle (pretreat-
ment, 24h, days 15 and 28). Blood samples were collected into
tubes containing preservative-free heparin (30mml
 1 blood, Leo
Laboratories Ltd, Princes Risborough, UK) and PHA (2mgml
 1
blood, HA 16/17, Murex Biotech Ltd, Dartford, UK), or heparin
alone as controls. All samples were collected and processed under
sterile and pyrogen-free conditions. Whole–blood samples were
incubated at 371C in a 5% CO2-saturated humidified incubator. At
24h post in vitro stimulation with PHA, the blood samples were
cool spun, the supernatant separated, flash frozen and stored at
 201C. Interleukin-6 (IL-6) was measured using the ELISA kit
D6050 (R & D Systems, Abingdon, UK) and TNF-a was measured
using DTA50 (R & D Systems, Abingdon, UK).
Statistical analysis
Wilcoxon matched-pairs signed-ranks test was used to analyse
changes in TNF-a and IL-6 levels with therapy (pretreatment vs.
24h sample and pretreatment vs. day 28 sample).
RESULTS
Patient characteristics
Baseline data for the patients are summarised in Table 1. Eight
patients had synchronous metastatic disease (i.e. primary disease
and metastasis) at presentation. Biopsy was performed for
histopathological diagnosis in these patients. They did not receive
adjunctive nephrectomy. The majority of patients (13 patients) had
more than one site of metastatic disease. Three patients had lung
metastasis only at the time of entry into the trial. A total of 181
infusions were administered with a median of 12 infusions per
patient (range 1–29). In all, 59 completed cycles were adminis-
tered; 10 patients received more than 2 and six patients received 2
or less cycles of therapy.
Disease response
A total of 13 patients were available for disease response evaluation
(three patients were not evaluable, one patient had one cycle of
therapy and refused further participation in the study, one patient
had two cycles but refused evaluation and one patient received less
than one cycle and died due to an unrelated cause). In 10 patients,
radiological assessment performed after the second cycle of
therapy showed no disease progression. Therefore, they continued
to receive bryostatin-1 beyond cycle two. Three patients achieved
stable disease (SD) lasting for 10.5, 8 and 5.5 months, respectively.
Patient one was treated with nephrectomy at initial presentation.
He relapsed with lung metastasis 15 months later and received
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linterferon therapy. However, he progressed within 3 months of
interferon treatment. He achieved stable disease for 10.5 months
while on bryostatin-1 therapy. Patient two, who presented with
synchronous metastatic disease, received interferon as first-line
treatment. Although he progressed within 4 months of interferon
therapy, he achieved stable disease lasting for 8 months on
bryostatin-1. He was later withdrawn from the trial because he
developed grade 4 haematuria possibly related to bryostatin-1. No
complete responses or partial responses were seen. In total, 10
patients had progressive disease within 4 months of initiating
bryostatin-1 therapy.
Toxicity data
Bryostatin-1 therapy was reasonably well tolerated. Myalgia (grade
3–2 pts, grade 2–2 pts, grade 1–4 pts), fatigue (grade 2–3 pts,
grade 1–4 pts), nausea (grade 2–3 pts, grade 1–5 pts), headache
(grade 2–3 pts), vomiting (grade 1–3 pts), anorexia (grade 1–3
pts), anaemia (grade 2–6 pts, grade 1–1 pts) and lymphopenia
(grade 2–6 pts, grade 1–4 pts) were the commonly reported side
effects probably, possibly or almost certainly related to bryostatin-
1. There were no treatment-related deaths. One patient died 4 days
after the first bryostatin-1 infusion. He presented acutely unwell
with worsening renal functions. He suffered cardiac arrest and
died. A detailed post-mortem examination reported perforated
duodenal ulcer as the cause of death. This was not considered to be
related to bryostatin-1. Dyskinetic tongue movements possibly
related to bryostatin-1 were seen in another patient. Spontaneous
grade 4 haematuria was seen in one patient. This was considered to
be due to bryostatin-1 and he was withdrawn from the trial.
Another patient developed grade 4 skin rash manifesting as scaly
and ulcerating lesion on the legs possibly related to bryostatin-1
(withdrawn from trial later at the patient’s request). Other grade 1
or 2 side effects reported were fever (one patient), constipation
(one patient), arthralgia (one patient), abdominal pain (three
patients), conjunctivitis (one patient), blurred vision (one patient),
insomnia (two patients), anxiety (one patient), palpitations
(one patient) and phlebitis (one patient). Only one patient had
catheter-related infection and inflammation (unrelated to
byrostatin-1). Grade 1 and 2 biochemical abnormalities
reported possibly were hypocalcaemia (five patients), hypoglycae-
mia (three patients), hyponatraemia (three patients), and
hyperkalaemia (two patients).
Biological activity
Assessment of biological activity of bryostatin-1 was performed in
six patients using the whole-blood cytokine release assay (Thavasu
et al, 1999). Briefly, whole blood from patients was stimulated with
PHA and release of cytokines IL-6 and TNF-a measured after 24h
incubation at 371C. The ability of bryostatin-1 therapy to alter this
response was assessed in sequential samples over a 28-day time
period (Figure 1). IL-6 production was significantly reduced in all
the six patients at day 28 compared to pretreatment values
(P¼0.03). The mean pretreatment IL-6 level was 943pgml
 1
(range 420–2271, standard deviation 755). The mean IL-6 level at
day 28 was 476pgml
 1 (range 253–1107, standard deviation 325).
There was no correlation between IL-6 level and disease response.
All the six patients who had reduced IL-6 response at day 28
progressed within 3 months of therapy. In three patients who had
disease stabilization, IL-6 level assessments were not performed.
Bryostatin-1 treatment did not affect the levels of TNF-a produced
in the whole-blood cytokine assay.
CONCLUSIONS
A total of 16 patients with metastatic renal cancer were recruited
into this multicentre phase II clinical trial. Three patients achieved
stabilisation of disease lasting for 10.5, 8 and 5.5 months,
respectively. No complete or partial responses were observed.
Bryostatin-1 was reasonably well tolerated and most of the side
effects were as expected from previous phase I studies. One patient
died 4 days after the first bryostatin-1 infusion. Perforated
duodenal ulcer was the cause of death in this patient and was
not considered to be due to bryostatin-1. Sudden unexplained
death was reported in a patient in another phase II trial of
bryostatin-1 (Pagliaro et al, 2000). Dyskinetic tongue movements
seen in one patient have not been reported before. Anaemia and
lymphopenia were of no obvious clinical consequence. The
mechanisms of biochemical abnormalities (hyponatraemia, hypo-
calcaemia, hypoglycaemia and hyperkalaemia) due to bryostatin-1
are unknown. Hyponatraemia was seen in five patients with head
and neck cancer in another phase II trial of bryostatin-1
(Brockstein et al, 2001). We investigated the role of IL-6 and
TNF-a as potential markers of biological effect of bryostatin-1.
Table 1 Baseline data
Total Number of patients 16
Males 11
Females 5
Median age 59 years (range 44–68)
Previous therapy (number of patients)
Nephrectomy 8
Interferon 9
Hormone therapy (megesterol/
medroxyprogesterone)
4
Radiotherapy 6
Time from diagnosis to systemic therapy
(number of patients)
0–24 months 13
X24 months 3
Baseline WHO performance status (number
of patients)
Zero 8
One 5
Two 3
Total number of bryostatin-1 infusions 181 (median 12 (range 1–29))
Pretreatment
24 h
Day 15
Day 28
2500
2000
1500
1000
500
0
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
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Figure 1 Illustrates IL-6 release in the whole-blood cytokine assay.
Samples were taken at set time points during therapy (pretreatment, 24h,
days 15 and 28). IL-6 was measured by ELISA. A rise in IL-6 levels was seen
in two patients (patients 1 and 4) after 24h of bryostatin-1. After 28 days
therapy, the production of IL-6 was reduced in all the six patients
(P¼0.03).
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levels within 24h after the initiation of bryostatin-1 therapy (Philip
et al, 1993; Jayson et al, 1995), we extended the time points to up to
day 28 to assess the long-term biological effect of bryostatin-1.
Two patients had a rise in IL-6 levels after 24h of therapy.
However, all the six patients tested showed reduction in IL-6 levels
at day 28, which was statistically significant. This probably
correlates with the in vitro effect of bryostatin-1, where initial
activation of PKC is followed by its rapid downregulation.
Reduction of IL-6 after repeated bryostatin-1 infusions may
represent the biological consequence of this effect on the signal
transduction pathway. Interestingly, recent studies confirm the
role of IL-6 in promoting angiogenesis and cancer progression
(Salgado et al, 1999, 2002; Benoy et al, 2002).
Phase II trials of bryostatin-1 have been reported in many
tumour types and several patients have achieved disease stabilisa-
tions in these studies (Propper et al, 1998; Gonzalez et al, 1999;
Bedikian et al, 2001; Brockstein et al, 2001). These trials have used
different doses and schedules of bryostatin-1. A previously
published phase II trial in kidney cancer patients used bryosta-
tin-1 at a dose of 25mgm
 2 administered as a 30min intravenous
infusion on days 1, 8 and 15 of a 28-day cycle. Two patients had
objective responses but methodological problems made disease
response assessment difficult (Pagliaro et al, 2000). Bryostatin-1
used at a dose of 35–40mgm
 2 given intravenously over 1h on
days 1, 8 and 15 of a 4-weekly cycle produced prolonged stable
disease or partial response in 25% of patients with renal cancer in a
recently reported phase II trial (Haas et al, 2003). Experimental
data suggest that bryostatin-1 may have a synergistic anticancer
effect with chemotherapy (Mohammad et al, 2000). In fact, early-
phase human trials of bryostatin-1 in combination with che-
motherapy (vincristine, paclitaxel and cisplatin) seem to suggest
that this approach is feasible and safe (Kaubisch et al, 1999;
Rosenthal et al, 1999; Varterasian et al, 2000). Newer bryostatin
analogues have also been synthesised recently and their role as
anticancer agents needs investigation (Wender et al, 1999). We
conclude that bryostatin-1 monotherapy does not have a major
impact on renal cancer metastasis. Future trials in combination
with immunotherapy or chemotherapy or the use of newer more
potent bryostatins may be more promising.
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